A detailed history of High Tower Advisors, LLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 10,486 shares of ABCL stock, worth $28,941. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,486
Previous 13,986 25.03%
Holding current value
$28,941
Previous $41,000 34.15%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.39 - $3.49 $8,365 - $12,215
-3,500 Reduced 25.03%
10,486 $27,000
Q2 2024

Aug 13, 2024

SELL
$2.73 - $4.73 $82,140 - $142,316
-30,088 Reduced 68.27%
13,986 $41,000
Q1 2024

May 06, 2024

BUY
$4.29 - $5.97 $13,311 - $18,524
3,103 Added 7.57%
44,074 $199,000
Q4 2023

Feb 12, 2024

BUY
$3.91 - $5.93 $27,088 - $41,083
6,928 Added 20.35%
40,971 $233,000
Q3 2023

Nov 08, 2023

BUY
$4.6 - $7.95 $156,597 - $270,641
34,043 New
34,043 $156,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $787M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.